Ivonib launch date

ivosidenibis produced by Taisho Pharmaceutical(Eisai Co., Ltd.) was developed and produced in 2014, and was launched in Japan in 20187menstruation The U.S.FDAapproved the marketing, and was approved for marketing by the State Food and Drug Administration of China in2022year2month9 Nikkei. It is an anti-tumor drug used to treat patients with IDH1gene mutations(changes)a type of cholangiocarcinoma).

The most common adverse reactions (≥20%)of ivosidenib are fatigue, arthralgia, leukocytosis, diarrhea, edema, nausea, dyspnea, mucositis, electrocardiogramQT prolongation, rash, cough, decreased appetite, myalgia, constipation and fever. The most common laboratory abnormalities (≥20%)are decreased hemoglobin, decreased calcium, decreased sodium, decreased magnesium, increased uric acid, decreased potassium, increased alkaline phosphatase, increased aspartate aminotransferase, decreased phosphate, and increased creatinine. Patients treated with ivosidenib may develop symptoms of differentiation syndrome, which may be fatal if untreated. Symptoms may include fever, dyspnea, hypoxia, pulmonary infiltrates, pleural or pericardial effusion, rapid weight gain or peripheral edema, hypotension, and hepatic, renal, or multiorgan dysfunction. If differentiation syndrome is suspected, initiate corticosteroid therapy and hemodynamic monitoring until symptoms resolve. Avonibu produced in Laos costs about 5,000 to 6,000 yuan per box, and the price is favorable. If you want to get more high-quality information, you can contact Yaode . Yaode will do its best to learn more about high-quality overseas drugs for you.

xa0